GlassScriptPhysician profile
Martin A Smith
NPI 1235491275
$754.59
in general payments reported to CMS, 2019-2025
20 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $31.55 · 2021: $12.20 · 2023: $70.05 · 2024: $258 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528 · Education: $59.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.79 |
| Education | $59.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $163.65 | 2019-2024 | Airsupra |
| Abbvie INC. | $84.02 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $61.70 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $59.80 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.69 | 2023-2024 | |
| Optinose US, INC. | $38.15 | 2024 | |
| Xeris Pharmaceuticals, INC. | $22.64 | 2025 | Recorlev |
| Amgen INC. | $20.87 | 2025 | Repatha, Otezla |
| Vivus LLC | $20.00 | 2024 | Qsymia |
| Novartis Pharmaceuticals Corporation | $19.66 | 2025 | |
| Axsome Therapeutics, INC. | $19.58 | 2024 | Auvelity |
| Evoke Pharma, INC. | $19.14 | 2025 | |
| Pfizer INC. | $19.07 | 2023 | |
| Vanda Pharmaceuticals INC. | $17.33 | 2024 | Hetlioz, Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.05 | 2024 | Flucelvax, Fluad |
| Regeneron Healthcare Solutions, INC. | $16.76 | 2025 | Dupixent |
| Lilly USA, LLC | $15.46 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.02 | 2025 | Voquezna |
| Galderma Laboratories, L.P. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.